Pharming Group N.V. (PHAR)
NASDAQ: PHAR · Real-Time Price · USD
8.00
-0.05 (-0.62%)
At close: Apr 14, 2025, 4:00 PM
8.36
+0.36 (4.50%)
After-hours: Apr 14, 2025, 4:05 PM EDT
Pharming Group Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Pharming Group stock have an average target of 30, with a low estimate of 14 and a high estimate of 39. The average target predicts an increase of 275.00% from the current stock price of 8.00.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Pharming Group stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 2 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $37 | Strong Buy | Reiterates | $37 | +362.50% | Mar 21, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $37 | Strong Buy | Reiterates | $37 | +362.50% | Mar 20, 2025 |
Oppenheimer | Oppenheimer | Buy Maintains $30 → $39 | Buy | Maintains | $30 → $39 | +387.50% | Mar 14, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $37 | Strong Buy | Reiterates | $37 | +362.50% | Mar 14, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $37 | Strong Buy | Reiterates | $37 | +362.50% | Dec 17, 2024 |
Financial Forecast
Revenue This Year
321.74M
from 297.20M
Increased by 8.26%
Revenue Next Year
353.03M
from 321.74M
Increased by 9.73%
EPS This Year
-0.04
from -0.02
EPS Next Year
-0.02
from -0.04
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 358.5M | 434.0M | 569.7M | ||
Avg | 321.7M | 353.0M | 436.1M | ||
Low | 284.3M | 273.7M | 323.3M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 20.6% | 34.9% | 61.4% | ||
Avg | 8.3% | 9.7% | 23.5% | ||
Low | -4.3% | -14.9% | -8.4% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -0.01 | 0.02 | 0.07 | ||
Avg | -0.04 | -0.02 | 0.03 | ||
Low | -0.06 | -0.06 | - |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.